684 related articles for article (PubMed ID: 17596875)
1. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma.
Matsuzaki K; Murata M; Yoshida K; Sekimoto G; Uemura Y; Sakaida N; Kaibori M; Kamiyama Y; Nishizawa M; Fujisawa J; Okazaki K; Seki T
Hepatology; 2007 Jul; 46(1):48-57. PubMed ID: 17596875
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B.
Murata M; Matsuzaki K; Yoshida K; Sekimoto G; Tahashi Y; Mori S; Uemura Y; Sakaida N; Fujisawa J; Seki T; Kobayashi K; Yokote K; Koike K; Okazaki K
Hepatology; 2009 Apr; 49(4):1203-17. PubMed ID: 19263472
[TBL] [Abstract][Full Text] [Related]
3. Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21(WAF1) pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells.
Li Q; Liu G; Yuan H; Wang J; Guo Y; Chen T; Zhai R; Shao D; Ni W; Tai G
Oncotarget; 2015 Feb; 6(6):4253-65. PubMed ID: 25714018
[TBL] [Abstract][Full Text] [Related]
4. Linker phosphorylation of Smad3 promotes fibro-carcinogenesis in chronic viral hepatitis of hepatocellular carcinoma.
Murata M; Yoshida K; Yamaguchi T; Matsuzaki K
World J Gastroenterol; 2014 Nov; 20(41):15018-27. PubMed ID: 25386050
[TBL] [Abstract][Full Text] [Related]
5. Smad2 and Smad3 phosphorylated at both linker and COOH-terminal regions transmit malignant TGF-beta signal in later stages of human colorectal cancer.
Matsuzaki K; Kitano C; Murata M; Sekimoto G; Yoshida K; Uemura Y; Seki T; Taketani S; Fujisawa J; Okazaki K
Cancer Res; 2009 Jul; 69(13):5321-30. PubMed ID: 19531654
[TBL] [Abstract][Full Text] [Related]
6. Smad3 phosphoisoform-mediated signaling during sporadic human colorectal carcinogenesis.
Matsuzaki K
Histol Histopathol; 2006 Jun; 21(6):645-62. PubMed ID: 16528675
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic Smad3 signaling induced by chronic inflammation is an early event in ulcerative colitis-associated carcinogenesis.
Kawamata S; Matsuzaki K; Murata M; Seki T; Matsuoka K; Iwao Y; Hibi T; Okazaki K
Inflamm Bowel Dis; 2011 Mar; 17(3):683-95. PubMed ID: 20602465
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor- suppression in rat hepatocellular carcinoma.
Nagata H; Hatano E; Tada M; Murata M; Kitamura K; Asechi H; Narita M; Yanagida A; Tamaki N; Yagi S; Ikai I; Matsuzaki K; Uemoto S
Hepatology; 2009 Jun; 49(6):1944-53. PubMed ID: 19418558
[TBL] [Abstract][Full Text] [Related]
9. Smad Phospho-Isoforms for Hepatocellular Carcinoma Risk Assessment in Patients with Nonalcoholic Steatohepatitis.
Suwa K; Yamaguchi T; Yoshida K; Murata M; Ichimura M; Tsuneyama K; Seki T; Okazaki K
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 31991602
[TBL] [Abstract][Full Text] [Related]
10. Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection.
Deng YR; Yoshida K; Jin QL; Murata M; Yamaguchi T; Tsuneyama K; Moritoki Y; Niu JQ; Matsuzaki K; Lian ZX
Clin Exp Immunol; 2014 Apr; 176(1):102-11. PubMed ID: 24372395
[TBL] [Abstract][Full Text] [Related]
11. c-Jun N-terminal kinase inhibitor favors transforming growth factor-β to antagonize hepatitis B virus X protein-induced cell growth promotion in hepatocellular carcinoma.
Wu YH; Ai X; Liu FY; Liang HF; Zhang BX; Chen XP
Mol Med Rep; 2016 Feb; 13(2):1345-52. PubMed ID: 26648552
[TBL] [Abstract][Full Text] [Related]
12. Smad3 and its phosphoisoforms are prognostic predictors of hepatocellular carcinoma after curative hepatectomy.
Kim SH; Ahn S; Park CK
Hepatobiliary Pancreat Dis Int; 2012 Feb; 11(1):51-9. PubMed ID: 22251470
[TBL] [Abstract][Full Text] [Related]
13. Smad3 phospho-isoform signaling in hepatitis C virus-related chronic liver diseases.
Yamaguchi T; Yoshida K; Murata M; Matsuzaki K
World J Gastroenterol; 2014 Sep; 20(35):12381-90. PubMed ID: 25253939
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylated Smad2 and Smad3 signaling: Shifting between tumor suppression and fibro-carcinogenesis in chronic hepatitis C.
Yamaguchi T; Matsuzaki K; Inokuchi R; Kawamura R; Yoshida K; Murata M; Fujisawa J; Fukushima N; Sata M; Kage M; Nakashima O; Tamori A; Kawada N; Tsuneyama K; Dooley S; Seki T; Okazaki K
Hepatol Res; 2013 Dec; 43(12):1327-42. PubMed ID: 23458062
[TBL] [Abstract][Full Text] [Related]
15. Loss of cooperative function of transforming growth factor-beta signaling proteins, smad3 with embryonic liver fodrin, a beta-spectrin, in primary biliary cirrhosis.
Mishra B; Tang Y; Katuri V; Fleury T; Said AH; Rashid A; Jogunoori W; Mishra L
Liver Int; 2004 Dec; 24(6):637-45. PubMed ID: 15566516
[TBL] [Abstract][Full Text] [Related]
16. Distortion of autocrine transforming growth factor beta signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells.
Sugano Y; Matsuzaki K; Tahashi Y; Furukawa F; Mori S; Yamagata H; Yoshida K; Matsushita M; Nishizawa M; Fujisawa J; Inoue K
Oncogene; 2003 Apr; 22(15):2309-21. PubMed ID: 12700666
[TBL] [Abstract][Full Text] [Related]
17. TGF-beta during human colorectal carcinogenesis: the shift from epithelial to mesenchymal signaling.
Matsuzaki K; Seki T; Okazaki K
Inflammopharmacology; 2006 Dec; 14(5-6):198-203. PubMed ID: 17093904
[TBL] [Abstract][Full Text] [Related]
18. Phospho-Smad3 signaling is predictive biomarker for hepatocellular carcinoma risk assessment in primary biliary cholangitis patients.
Nakamura N; Yoshida K; Tsuda R; Murata M; Yamaguchi T; Suwa K; Ichimura M; Tsuneyama K; Matsuzaki K; Nakano T; Hirohara J; Seki T; Okazaki K; Gershwin ME; Naganuma M
Front Biosci (Landmark Ed); 2021 Dec; 26(12):1480-1492. PubMed ID: 34994163
[TBL] [Abstract][Full Text] [Related]
19. SEN virus infection influences the pathological findings in liver but does not affect the incidence of hepatocellular carcinoma in patients with chronic hepatitis C and liver cirrhosis.
Moriyama M; Mikuni M; Matsumura H; Nakamura H; Oshiro S; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Tanaka N; Arakawa Y
Liver Int; 2005 Apr; 25(2):226-35. PubMed ID: 15780043
[TBL] [Abstract][Full Text] [Related]
20. Smad3 Phospho-Isoform Signaling in Nonalcoholic Steatohepatitis.
Yamaguchi T; Yoshida K; Murata M; Suwa K; Tsuneyama K; Matsuzaki K; Naganuma M
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
